EXPERIMENTAL DRUGS / POTENTIAL ANTIBIOTIC THERAPIES AGAINST M. ULCERANS
Q203 (Telacebec)
TARGET PROTEIN
cytochrome bcc-aa3 terminal oxidase
MECHANISM OF ACTION
Bactericidal activity
DRUG INTERACTION PHASE (APPROVED, INVESTIGATIONAL, EXPERIMENTAL)
Investigational
MODE OF ADMINISTRATION
Oral
LINK TO PUBMED
https://pubmed.ncbi.nlm.nih.gov/32631818/
EXTERNAL LINKS
PubChem Compound 68234908
REFERENCE
Sangeeta S., T., Nitin Pal, K., Marie-Th?r?se, R., Gerd, P., & Pethe, K. (2020). Toward a Single-Dose Cure for Buruli Ulcer. Antimicrobial Agents and Chemotherapy, 64(9). https://doi.org/10.1128/AAC.00727-20